Stockscreener 앱 받기
0.93
2.47%
0.0224
시간 외 거래:
.90
-0.03
-3.23%
전일 마감가:
$0.9076
열려 있는:
$0.92
하루 거래량:
62,021
Relative Volume:
0.31
시가총액:
$68.84M
수익:
$8.23M
순이익/손실:
$-32.49M
주가수익비율:
-1.7547
EPS:
-0.53
순현금흐름:
$-19.91M
1주 성능:
-8.82%
1개월 성능:
+8.18%
6개월 성능:
-30.60%
1년 성능:
-33.57%
1일 변동 폭
$0.9007
$0.9399
1주일 범위
$0.90
$1.05
52주 변동 폭
$0.7737
$1.65
Clearside Biomedical Inc Stock (CLSD) Company Profile
명칭
Clearside Biomedical Inc
전화
678-270-3631
주소
900 NORTH POINT PARKWAY, ALPHARETTA, GA
CLSD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.93 | 68.84M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-21 | 개시 | Chardan Capital Markets | Buy |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2021-12-15 | 재개 | Wedbush | Outperform |
| 2021-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-05-13 | 개시 | ROTH Capital | Buy |
| 2019-08-09 | 다운그레이드 | Needham | Buy → Hold |
| 2018-11-05 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2018-11-05 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2018-11-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-06 | 재확인 | Needham | Buy |
| 2017-05-25 | 개시 | JMP Securities | Mkt Outperform |
| 2017-02-24 | 개시 | JP Morgan | Overweight |
| 2016-11-10 | 재확인 | Needham | Buy |
| 2016-10-24 | 재확인 | Stifel | Buy |
모두보기
Clearside Biomedical Inc 주식(CLSD)의 최신 뉴스
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Key Strategic Updates Expected: Clearside Biomedical CEO Takes Stage at Major Healthcare Conference - Stock Titan
Clearside Biomedical’s (CLSD) Buy Rating Reaffirmed at HC Wainwright - Defense World
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge - Investing.com Australia
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge By Investing.com - Investing.com South Africa
Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD - MSN
Clearside Biomedical (NASDAQ:CLSD) Earns “Buy” Rating from Chardan Capital - Defense World
Needham & Company LLC Has Lowered Expectations for Clearside Biomedical (NASDAQ:CLSD) Stock Price - Defense World
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations - Yahoo Finance
JMP reiterates Clearside Biomedical stock with $5 target By Investing.com - Investing.com Canada
Clearside Biomedical’s Positive Earnings Call Highlights Progress and Challenges - TipRanks
Stifel maintains Clearside Biomedical buy rating, $8 target By Investing.com - Investing.com UK
Clearside Biomedical (CLSD) Prepares for Phase 3 Trials, Seeks F - GuruFocus
Clearside Biomedical Reports Net Loss for Fourth Quarter and Full Year 2024 - VisionMonday.com
Clearside Biomedical Reports 2024 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast - Investing.com India
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Clearside Biomedical Reports 2024 Financial Results and Updates - TipRanks
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings: EPS Matches Es - GuruFocus
Clearside Biomedical Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Clearside Biomedical earnings matched, revenue topped estimates - Investing.com
CLEARSIDE BIOMEDICAL Earnings Results: $CLSD Reports Quarterly Earnings - Nasdaq
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside Reports 95% Revenue Decline, But Secures Critical FDA Agreement for Phase 3 Trial - Stock Titan
Exploring Clearside Biomedical's Earnings Expectations - Benzinga
Clearside Biomedical Announces Six Abstracts Accepted for - GlobeNewswire
Game-Changing Eye Treatment Data: Clearside to Present Phase 2b Results at ARVO 2025 - Stock Titan
Clearside Biomedical Presents Comparative Data on CLS-AX for Wet AMD at 2025 Wet AMD & Diabetic Eye Disease Summit - Nasdaq
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet - GlobeNewswire
Clearside's Revolutionary Eye Treatment Platform Targets $12B Wet AMD Market After FDA Green Light - StockTitan
Clearside Biomedical (NASDAQ:CLSD) Downgraded to Sell Rating by StockNews.com - Defense World
Clearside Biomedical to Report Fourth Quarter and Full Year - GlobeNewswire
Clearside Biomedical, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025 - Nasdaq
Clearside Biomedical Q4 Earnings: Key Date Announced for Critical Year-End Financial Results - StockTitan
Clearside Biomedical (CLSD) Projected to Post Earnings on Tuesday - Defense World
HC Wainwright Reiterates “Buy” Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World
Clearside Biomedical, Inc. to Host Earnings Call - ACCESS Newswire
Clearside Biomedical Announces Successful End-of-Phase 2 - GlobeNewswire
Buy Rating on Clearside Biomedical: Strategic Advancements in CLS-AX Program for wAMD - TipRanks
Promising Potential of Clearside Biomedical’s CLS-AX Treatment Justifies Buy Rating - TipRanks
Clearside Biomedical (CLSD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Clearside Biomedical announces successful End-of-Phase 2 meeting for CLS-AX - TipRanks
Can This New Wet AMD Treatment Challenge the $12B Market? FDA Says Yes to Phase 3 - StockTitan
Clearside Biomedical stock hits 52-week low at $0.79 - Investing.com
Clearside Biomedical Inc. Revolutionizes Panuveitis Treatment With Innovative Xipere Product: Key Trend in ... - WhaTech
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Brokerages - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Buys $13,800.00 in Stock - MarketBeat
Clearside Biomedical director Thorp Clay buys $13,800 in stock By Investing.com - Investing.com South Africa
Clearside Biomedical Inc (CLSD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):